{"nctId":"NCT02763579","briefTitle":"A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)","startDateStruct":{"date":"2016-06-07","type":"ACTUAL"},"conditions":["Small Cell Lung Carcinoma"],"count":503,"armGroups":[{"label":"Atezolizumab + Carboplatin + Etoposide","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","Drug: Carboplatin","Drug: Etoposide"]},{"label":"Placebo + Carboplatin + Etoposide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Carboplatin","Drug: Etoposide","Drug: Placebo"]}],"interventions":[{"name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","otherNames":["MPDL3280A, RO5541267, Tecentriq"]},{"name":"Carboplatin","otherNames":[]},{"name":"Etoposide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \\[VALG\\] staging system)\n* No prior systemic treatment for ES-SCLC\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Measurable disease, as defined by RECIST v1.1\n* Adequate hematologic and end organ function\n* Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC\n\nExclusion Criteria:\n\n* Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation\n* Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* Pregnant or lactating women\n* History of autoimmune disease\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Positive test result for human immunodeficiency virus (HIV)\n* Active hepatitis B or hepatitis C\n* Severe infections at the time of randomization\n* Significant cardiovascular disease\n* Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1 (PD-1), and anti-PD-L1 therapeutic antibody\n* History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population","description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least 20% increase in the sum of the longest diameter of target lesions compared to baseline, or unequivocal progression in non-target lesion(s), or the appearance of new lesion(s).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"4.2"},{"groupId":"OG001","value":"5.2","spread":"4.4"}]}]}]},{"type":"PRIMARY","title":"Duration of Overall Survival (OS) in the Global Population","description":"OS is defined as the time from randomization to death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"9.3"},{"groupId":"OG001","value":"12.3","spread":"10.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response Rate (ORR) as Assessed by the Investigator Using RECIST v1.1 in the Global Population","description":"Objective response (OR) is defined as complete response (CR) or partial response (PR) as determined by the investigator according to RECIST v1.1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"74.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 in the Global Population","description":"DOR is defined as the time interval from first occurrence of a documented objective response to the time of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever comes first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS Rate at 6 Months and at 1 Year in Global Population","description":"PFS rates at 6 months and at 1 year is defined as the proportion of participants who are alive without disease progression 6 months and 1 year after randomization, respectively.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.39","spread":null},{"groupId":"OG001","value":"30.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.35","spread":null},{"groupId":"OG001","value":"12.62","spread":null}]}]}]},{"type":"SECONDARY","title":"OS Rate at 1 Year and 2 Years in the Global Population","description":"OS rates at 1 and 2 years is defined as the proportion of participants who are alive 1 year and 2 years after randomization, respectively.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.23","spread":null},{"groupId":"OG001","value":"51.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) Per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30) and Supplemental Lung Cancer Module (QLQ-LC13) in the Global Population","description":"TTD according to the EORTC QLQ-C30 and EORTC QLQ-LC13 measures were evaluated in each of the following linearly transformed symptom scores: cough, dyspnea (single item), dyspnea (multi-item subscale), chest pain, or arm/shoulder pain. The linear transformation gives each individual symptom subscale a possible score of 0 to 100. For the symptom to be considered \"deteriorated,\" a score increase of ≥10 points above baseline must be held for at least two consecutive assessments or an initial score increase of ≥10 points is followed by death within 3 weeks from the last assessment. A ≥ 10-point change in the symptoms subscale score is perceived by participants as clinically significant.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Adverse Event in the Global Population","description":"The percentage of participants with at least one adverse event in the global population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Drug Antibodies (ADA) to Atezolizumab in the Global Population","description":"The baseline prevalence and post-baseline incidence of ADAs against atezolizumab.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab in the Global Population","description":"Atezolizumab maximum observed plasma concentration (Cmax; 30 minutes following the end of the atezolizumab infusion) for each respective day.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":"135"}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab in the Global Population","description":"Atezolizumab pre-dose plasma concentration (Cmin) for each respective day.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.6","spread":"32.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":"56.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":"73.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":"63.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":"43.4"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Carboplatin in the Global Population","description":"Plasma concentration of carboplatin in the Global population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13300","spread":"4880"},{"groupId":"OG001","value":"11200","spread":"5060"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7200","spread":"1880"},{"groupId":"OG001","value":"6860","spread":"1670"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":"58.3"},{"groupId":"OG001","value":"126","spread":"48.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13900","spread":"3590"},{"groupId":"OG001","value":"11300","spread":"5090"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7180","spread":"1630"},{"groupId":"OG001","value":"6540","spread":"2200"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Etoposide in the Global Population","description":"Plasma concentration of etoposide in the Global Population.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17000","spread":"3640"},{"groupId":"OG001","value":"19400","spread":"2860"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11100","spread":"2010"},{"groupId":"OG001","value":"12600","spread":"1960"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7640","spread":"2360"},{"groupId":"OG001","value":"7300","spread":"1230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16600","spread":"2180"},{"groupId":"OG001","value":"17700","spread":"3600"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12400","spread":"3740"},{"groupId":"OG001","value":"12200","spread":"2810"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6740","spread":"1230"},{"groupId":"OG001","value":"7960","spread":"2090"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":69,"n":196},"commonTop":["Anaemia","Alopecia","Nausea","Neutropenia","Neutrophil count decreased"]}}}